Steroid use and misuse: a key performance indicator in the management of IBD Frontline Gastroenterol. 2020 Apr 2;12(3):207-213.doi: 10.1136/flgastro-2019-101288. eCollection 2021. Jonathan Blackwell 1 2, Christian Selinger 3 4, Tim Raine 5, Gareth Parkes 6, Melissa A Smith 7 8, Richard Pollok 1 9 |
Author information
Abstract Corticosteroids remain an important tool for inducing remission in inflammatory bowel disease (IBD) but they have no role in maintenance of remission. The significant adverse side effect profile of these drugs means their use should be avoided where possible or measures taken to reduce their risk. Despite an expanding array of alternative therapies, corticosteroid dependency and excess remain common. Appropriate steroid use is now regarded a key performance indicator in the management of IBD. This article aims to outline indications for corticosteroid use in IBD, their risks and strategies to reduce their use and misuse. |
© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.